The Center for Breakthrough Medicines at Discovery Labs Appoints Matthew Snyder as Associate Director, Engineering & Facilities

Published on :

The Center for Breakthrough Medicines at Discovery Labs, an ecosystem accelerating the path to commercialization for cell and gene therapy companies, has appointed Matthew Snyder to the role of Associate Director, Engineering & Facilities. Mr. Snyder will be responsible for establishing the critical support services necessary for laboratory and manufacturing operations. These include setup of a comprehensive safety program; implementation of equipment tracking and maintenance and calibration management systems; interface coordination between site infrastructure utilities, building monitoring and process control systems; and technical engineering support for process operations and facility design.

NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs

Published on :

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Published on :

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019. Leveraging its proprietary REVEAL-TxTM disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon’s early discovery pipeline.

Patent for Patients: A Boon for Cancer Immunotherapy

Published on :

Over the recent decades, cancer immunotherapy research has made significant advances. In our continued quest to cure cancer, a commercial incentive is necessary to counterbalance the costs and risks associated with the research and development of cancer immunotherapies and to encourage new inventions.

In Conversation: Dr. Vipin K. Garg, CEO of Altimmune

Published on :

Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.

Mason Start-up Ceres Nanosciences Experiences Big Wins and Increases Footprint in Prince William County

Published on :

Ceres Nanosciences, a Northern Virginia bioscience company spun out of George Mason University that specializes in diagnostic products and workflows, has opened a 12,000-square-foot advanced particle manufacturing plant in Prince William County’s Innovation Park.

Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases

Published on :

Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases, launches today with $10 million in financing and headquarters in the Philadelphia region’s leading gene therapy epicenter. 4BIO Capital and UPMC Enterprises co-led the Seed financing with participation from CureDuchenne Ventures, JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.

4 Ways A Strong Lab Professionals Community Can Impact Your Career

Published on :

One of the key contributors to building a great career is surrounding yourself with great mentors and a good network or community of professionals you can go to for help. While talking to BioBuzz and understanding their community efforts, I thought it might be a good time to share what aspects of a good community make up its foundation.

5 Questions with Nikki Marchan, MPH. Senior Specialist, Antimicrobial Resistance, Association of Public Health Laboratories

Published on :

Nikki Marchan is public health professional who is passionate about progressing the study of infectious diseases for enhanced prevention, detection, and response. As a Senior Specialist with the Association of Public Health Laboratories, she provides support for laboratory and surveillance activities and works on behalf of and in collaboration with public health laboratories, federal partners, and other public health organizations.